Skip to main content
Signal8

Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

$GILDPress releaseJun 8, 2026, 4:30 PM ETRead the release

Gilead and Merck discontinued the Phase 3 KEYNOTE-D46/EVOKE-03 study of Trodelvy plus KEYTRUDA in metastatic non-small cell lung cancer. The external Data Monitoring Committee recommended stopping the trial after a pre-specified analysis showed PFS improvement was not statistically significant and the probability of achieving significant OS is unlikely. The safety profile of the combination was consistent with known risks, with no new safety signals identified.

Key figures

Drug Name
Trodelvy (sacituzumab govitecan-hziy)
Phase Of Trial
Phase 3
Study name
KEYNOTE-D46/EVOKE-03
Patient enrollment
620

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    GILD: Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study — AI Analysis | Signal8